How Long Suboxone Stays in Your System

The honest answer starts with what is missing. This site publishes detection figures from one federal table, and buprenorphine is not in it. Nor is buprenorphine on the federal workplace panel. The rule at 49 CFR 40.85 lists the substances a laboratory must test for, and buprenorphine is not among them [3].

So this page gives no urine window, no blood window and no hair window for Suboxone. Not because the topic is awkward, but because we do not have a federal figure to give, and a number without a source behind it is worse than none.

What we can give you is the pharmacology from the medicine’s own FDA label, what the standard panel actually covers, and why a result involving a prescribed medicine is a different conversation from a result involving anything else. Our overview of buprenorphine in treatment covers the medicine itself.

How Long Suboxone Is Detectable: The Short Answer

No federal source we cite publishes one.

The table this site uses is SAMHSA’s Treatment Improvement Protocol 47, Appendix B. Its Urine Toxicology Detection Periods for Different Substances covers amphetamines, barbiturates, benzodiazepines, cocaine, cannabinoids, ethanol, opioids such as codeine and morphine, methadone and several others [1]. Buprenorphine has no row there.

The same gap appears in workplace rules. The Department of Transportation regulation at 49 CFR 40.85 sets cutoffs for nine analyte groups: marijuana metabolites, the cocaine metabolite, codeine and morphine, hydrocodone and hydromorphone, oxycodone and oxymorphone, 6-acetylmorphine, phencyclidine, amphetamine and methamphetamine, and MDMA and MDA [3]. Buprenorphine is absent from that list too.

That has a practical consequence worth stating plainly. The federal workplace panel, whose nine analyte groups are listed above, is not looking for Suboxone. Specialized buprenorphine assays do exist, and some employers, courts and treatment programs order them. They are ordered on purpose, separately, because the routine panel does not cover this medicine.

If someone has told you a precise number of days for Suboxone, ask them which federal table it came out of. We could not find one.

Urine, Blood, Saliva and Hair: What a Test Can and Cannot Show

Appendix B carries a second table on specimens rather than substances, and it is useful here even without a buprenorphine row [1].

It describes urine as a mature method that finds only recent use and needs costly confirmation to be accurate [1]. Blood it calls accurate but invasive and expensive, and says it detects only current use [1]. Saliva has a very short detection time and a mouth that is easily contaminated [1]. Hair measures long-term use, but the table calls it costly and slow, with no dose-response relation established [1].

Read that last phrase twice. No dose-response relation established means a hair result cannot tell anyone how much was taken. The appendix says something similar about findings in general. They cannot determine when a drug was taken, how much, how it was taken, or how impaired a person was [1].

So even where a specialized assay does find buprenorphine, it establishes presence. It does not establish a pattern, a quantity or a problem. That distinction carries most of the weight on this page.

Suboxone Half-Life and What That Actually Means

A half-life is not a detection window, and the label gives half-lives.

Suboxone is buprenorphine with naloxone. Buprenorphine is a partial agonist at the mu-opioid receptor; naloxone is an opioid antagonist [2]. The two clear at very different speeds.

Taken under the tongue or against the cheek, buprenorphine has a mean elimination half-life ranging from 24 to 42 hours [2]. Naloxone’s mean elimination half-life ranges from 2 to 12 hours [2]. Buprenorphine is therefore a long-acting medicine by design. That is part of why it can be dosed the way a prescriber chooses to dose it.

A half-life describes how long a body takes to clear half of what is circulating. A detection window describes how long an assay can still find a trace above a defined cutoff. The second depends on which test was ordered. Since no federal table gives that figure for buprenorphine, this page stops at the half-life.

Why the Same Prescription Clears Differently in Different People

The label answers this one directly, and the answer is mostly about the liver.

In people with mild liver impairment, the label reports no clinically significant change [2]. In moderate and severe impairment it reports higher plasma levels and longer half-life values for both buprenorphine and naloxone [2]. The effect on naloxone is the larger of the two [2]. People with hepatitis C but no sign of liver impairment showed no clinically significant change [2].

Other medicines matter as well. The label notes that drugs which inhibit the CYP3A4 enzyme can raise buprenorphine levels, and that inducers can lower them [2]. A lower level can bring on withdrawal in someone whose body has adapted to the medicine [2].

Appendix B adds the general version of the same point, for any substance and any test. How long something can be found depends on the drug’s own chemistry, how fast a body breaks it down and clears it, how much was taken and for how long, the sensitivity of the assay, and individual differences in health, diet, weight and fluid intake [1].

Our page on how tolerance differs from addiction covers the other variable people expect to be simple.

False Positives and What Else Can Trigger Them

Appendix B flags cross-reactivity as a bigger concern for amphetamines, benzodiazepines and opioids than for cocaine or marijuana [1].

That matters here in an indirect way. Because buprenorphine is not on the federal panel, an “opiates” result on a routine screen is not about Suboxone at all. It concerns the codeine and morphine group, which is one of the nine the rule lists [3]. Someone in buprenorphine treatment who returns a positive opiate screen has a separate question to answer, and it is not answered by their prescription.

Federal testing is built in two stages for exactly these reasons. The rule sets one cutoff for the initial test and another for the confirmatory test [3]. A first result is a signal. The confirmatory step is what a laboratory stands behind. Appendix B calls gas chromatography with mass spectrometry the gold standard, while noting that it is costly [1].

One more practical point. Workplace programs have a medical review officer, and a valid prescription is precisely the sort of thing that role exists to weigh. Raise it there and with the prescriber, in advance where you can.

Detection Windows Are Not a Safety Measure

For most substances this section argues that a clear result proves nothing about health. For a prescribed medicine the argument runs the other way as well.

Buprenorphine is one of three medications the FDA has approved for opioid use disorder, alongside methadone and naltrexone [5]. A result showing it is usually evidence that someone is in treatment. Reading that as a problem gets the situation exactly backwards, and people have lost jobs and custody hearings over the confusion.

So this page publishes no timing advice, no dilution methods and no technique aimed at any test result, for either direction of that worry. If a test is coming and a prescription is genuine, the fix is documentation and the medical review officer, not arithmetic.

And if the reason for reading this is that use has moved outside the prescription, that is a different problem with a better answer than a calendar. The label records that some people misuse buprenorphine and naloxone combinations by injection or through the nose [2]. That pattern is worth naming to a clinician rather than managing alone. Our guide to the signs that use has become a problem sets out what to look for.

When Frequent Suboxone Use Has Become Dependence

Here the label is careful in a way that ordinary conversation is not.

Buprenorphine is a partial agonist at the mu-opioid receptor, and chronic administration produces physical dependence of the opioid type [2]. That dependence shows itself as moderate withdrawal signs and symptoms after abrupt discontinuation or a rapid taper [2]. This is expected. It is what the medicine does.

The patient section of the same label states the distinction in one line: physical dependence is not the same as drug addiction [2]. MedlinePlus is equally direct about the practical consequence. Do not stop taking buprenorphine, or buprenorphine and naloxone, without talking to your doctor [4].

What marks a substance use disorder is a pattern of behavior rather than the presence of dependence. Taking more than prescribed. Taking it by a route it was not prescribed for. Trouble controlling use, and use continuing despite harm.

If that describes what is happening, the next step is a conversation with the prescriber, not a decision to stop. Our page on withdrawal symptoms describes what stopping can involve across drug classes.

Getting Help With Suboxone Use

Two different readers reach this heading, and the advice differs.

If you are prescribed Suboxone and it is working, the help you may need is administrative. Documentation for a testing program. A conversation with a medical review officer. A prescriber who will write what you need in advance of a review.

If use has moved outside the prescription, or if other substances are involved, an assessment is the step. That is a conversation with a clinician who takes the whole history and recommends a level of care. The Recovery Village Cherry Hill at Cooper publishes six on its own page: medical detox, inpatient treatment, partial hospitalization programming, intensive outpatient programming, outpatient programming and aftercare planning [6].

Nobody should arrive having ruled options out. Our levels of care explainer sets out what separates them, and our page on how admission works gives the order of events. Coverage is worth checking first rather than last, and our guide to whether insurance covers rehab explains what a benefits check produces.

Frequently Asked Questions

Sources

1. Center for Substance Abuse Treatment. (2006). Substance Abuse: Clinical Issues in Intensive Outpatient Treatment (TIP 47), Appendix B: Urine Collection and Testing Procedures and Alternative Methods for Monitoring Drug Use. Substance Abuse and Mental Health Services Administration. https://www.ncbi.nlm.nih.gov/books/NBK64092/
2. U.S. National Library of Medicine. (2026). Buprenorphine and Naloxone Sublingual Film — Full Prescribing Information: Clinical Pharmacology, Warnings and Precautions, Drug Abuse and Dependence. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4210afeb-474c-d842-d68e-af7e0021851a
3. Legal Information Institute. 49 CFR 40.85 — What drugs do laboratories test for?. Cornell Law School. https://www.law.cornell.edu/cfr/text/49/40.85
4. U.S. National Library of Medicine. Buprenorphine Sublingual and Buccal (opioid dependence). MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a605002.html
5. U.S. Food and Drug Administration. Information about Medications for Opioid Use Disorder (MOUD). https://www.fda.gov/drugs/food-and-drug-administration-overdose-prevention-framework/information-about-medications-opioid-use-disorder-moud
6. The Recovery Village. The Recovery Village Cherry Hill at Cooper — Levels of Care. Advanced Recovery Systems. https://www.therecoveryvillage.com/locations/cherry-hill/

This page is for general information and is not medical advice. Only a licensed clinician who knows your history can tell you what is right for you. If you or someone you know is in immediate danger, call 911. For free, confidential support 24/7, call or text 988.

Author

Kevin Wandler, MD

Chief Medical Officer, The Recovery Village